Pipeline
Discover our 18 studies
From discovery to phase III in oncology and bacterial infections
Our Drug Development Business Model
Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners to maximize patient access across the globe.
In-licensing Deal Focus
Our in-licensed compounds benefit from smart drug development leading to better patient treatment & value creation. We look for promising oncology and antibacterial compounds to transform them into valuable treatments. Want to partner with us? Discover our selection criteria
- Partners
- Universities, Biotech, Big pharma
- Main areas
- Oncology, Bacterial Infections
- Development stages
- From candidate to clinical phase I
- Molecules
- Small molecules, antibodies and peptides
Leadership team
Discover the members who guide and bring long-term vision to drug development